HRP20150573T1 - KO-KRISTALNI OBLIK „A“ METILPARABENA OD [4-(3-FLUORO-5-TRIFLUOROMETIL-PIRIDIN-2-IL)-PIPERAZIN-1-IL]-[5-METANSULFONIL-2-((S)-2,2,2-TRIFLUORO-1-METIL-ETOKSI)-FENIL]-METANONA - Google Patents

KO-KRISTALNI OBLIK „A“ METILPARABENA OD [4-(3-FLUORO-5-TRIFLUOROMETIL-PIRIDIN-2-IL)-PIPERAZIN-1-IL]-[5-METANSULFONIL-2-((S)-2,2,2-TRIFLUORO-1-METIL-ETOKSI)-FENIL]-METANONA

Info

Publication number
HRP20150573T1
HRP20150573T1 HRP20150573TT HRP20150573T HRP20150573T1 HR P20150573 T1 HRP20150573 T1 HR P20150573T1 HR P20150573T T HRP20150573T T HR P20150573TT HR P20150573 T HRP20150573 T HR P20150573T HR P20150573 T1 HRP20150573 T1 HR P20150573T1
Authority
HR
Croatia
Prior art keywords
metilparaben
methansulphonyl
piridin
methanone
piperazin
Prior art date
Application number
HRP20150573TT
Other languages
English (en)
Croatian (hr)
Inventor
André BUBENDORF
Annette Deynet-Vucenovic
Ralph Diodone
Olaf Grassmann
Kai Lindenstruth
Emmanuel Pinard
Franziska E. Rohrer
Urs Schwitter
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38988312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20150573(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20150573T1 publication Critical patent/HRP20150573T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
HRP20150573TT 2006-12-28 2007-12-18 KO-KRISTALNI OBLIK „A“ METILPARABENA OD [4-(3-FLUORO-5-TRIFLUOROMETIL-PIRIDIN-2-IL)-PIPERAZIN-1-IL]-[5-METANSULFONIL-2-((S)-2,2,2-TRIFLUORO-1-METIL-ETOKSI)-FENIL]-METANONA HRP20150573T1 (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06127269 2006-12-28
PCT/EP2007/064104 WO2008080821A1 (en) 2006-12-28 2007-12-18 Crystalline forms glyt1
EP07857734.3A EP2114405B1 (en) 2006-12-28 2007-12-18 methylparaben cocrystal form "A" of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2- ((S) -2,2,2-trifluoro- 1 -methyl-ethoxy) -phenyl] -methanone

Publications (1)

Publication Number Publication Date
HRP20150573T1 true HRP20150573T1 (xx) 2015-07-03

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150573TT HRP20150573T1 (xx) 2006-12-28 2007-12-18 KO-KRISTALNI OBLIK „A“ METILPARABENA OD [4-(3-FLUORO-5-TRIFLUOROMETIL-PIRIDIN-2-IL)-PIPERAZIN-1-IL]-[5-METANSULFONIL-2-((S)-2,2,2-TRIFLUORO-1-METIL-ETOKSI)-FENIL]-METANONA

Country Status (33)

Country Link
US (5) US20080214561A1 (OSRAM)
EP (1) EP2114405B1 (OSRAM)
JP (1) JP4799666B2 (OSRAM)
KR (1) KR101130146B1 (OSRAM)
CN (1) CN101573114A (OSRAM)
AR (1) AR064545A1 (OSRAM)
AU (1) AU2007341356B2 (OSRAM)
BR (1) BRPI0720829B8 (OSRAM)
CA (1) CA2673667A1 (OSRAM)
CL (1) CL2007003830A1 (OSRAM)
CO (1) CO6190613A2 (OSRAM)
CR (1) CR10846A (OSRAM)
CY (1) CY1116350T1 (OSRAM)
DK (1) DK2114405T3 (OSRAM)
EC (1) ECSP099471A (OSRAM)
ES (1) ES2535040T3 (OSRAM)
HR (1) HRP20150573T1 (OSRAM)
HU (1) HUE025032T2 (OSRAM)
MA (1) MA31029B1 (OSRAM)
MX (1) MX2009006859A (OSRAM)
MY (1) MY188367A (OSRAM)
NO (1) NO342150B1 (OSRAM)
NZ (1) NZ577502A (OSRAM)
PE (1) PE20081556A1 (OSRAM)
PL (1) PL2114405T3 (OSRAM)
PT (1) PT2114405E (OSRAM)
RS (1) RS53910B1 (OSRAM)
RU (1) RU2463295C2 (OSRAM)
SI (1) SI2114405T1 (OSRAM)
TW (1) TWI388552B (OSRAM)
UA (1) UA100232C2 (OSRAM)
WO (1) WO2008080821A1 (OSRAM)
ZA (1) ZA200904423B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573114A (zh) 2006-12-28 2009-11-04 弗·哈夫曼-拉罗切有限公司 结晶形式glyt1
WO2010099323A1 (en) * 2009-02-26 2010-09-02 Thar Pharmaceuticals, Inc. Crystalization of pharmaceutical compounds
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
EA201401312A1 (ru) * 2012-05-25 2015-09-30 Басф Се КРИСТАЛЛИЧЕСКАЯ ФОРМА В 1,5-ДИМЕТИЛ-6-ТИОКСО-3-(2,2,7-ТРИФТОР-3-ОКСО-4-(ПРОП-2-ИНИЛ)-3,4-ДИГИДРО-2Н-БЕНЗО[b][1,4]ОКСАЗИН-6-ИЛ)-1,3,5-ТРИАЗИНАН-2,4-ДИОНА
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
CA3166938A1 (en) 2020-01-09 2021-07-15 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
WO2022014396A1 (ja) * 2020-07-13 2022-01-20 日本碍子株式会社 精製方法
JP2024518091A (ja) * 2021-05-14 2024-04-24 ディスク・メディシン・インコーポレイテッド グリシン輸送阻害剤を用いて赤血球増殖性プロトポルフィリン症、x連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法
JP2024520391A (ja) * 2021-05-27 2024-05-24 ディスク・メディシン・インコーポレイテッド ビトペルチンの固体形態を用いて赤血球増殖性プロトポルフィリン症、x連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
RS53252B (sr) * 2003-08-11 2014-08-29 F.Hoffmann-La Roche Ag. Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1
CN101573114A (zh) 2006-12-28 2009-11-04 弗·哈夫曼-拉罗切有限公司 结晶形式glyt1

Also Published As

Publication number Publication date
PE20081556A1 (es) 2008-11-28
ECSP099471A (es) 2009-07-31
CN101573114A (zh) 2009-11-04
RS53910B1 (sr) 2015-08-31
EP2114405B1 (en) 2015-03-11
MX2009006859A (es) 2009-07-03
UA100232C2 (uk) 2012-12-10
US20110295007A1 (en) 2011-12-01
RU2009124113A (ru) 2011-02-10
KR101130146B1 (ko) 2012-03-28
BRPI0720829B8 (pt) 2021-05-25
ZA200904423B (en) 2010-05-26
SI2114405T1 (sl) 2015-06-30
CA2673667A1 (en) 2008-07-10
US8039473B2 (en) 2011-10-18
NZ577502A (en) 2012-02-24
NO20092358L (no) 2009-06-22
EP2114405A1 (en) 2009-11-11
WO2008080821A1 (en) 2008-07-10
MA31029B1 (fr) 2009-12-01
PL2114405T3 (pl) 2015-08-31
CR10846A (es) 2009-08-12
US20080214561A1 (en) 2008-09-04
US20100311971A1 (en) 2010-12-09
JP4799666B2 (ja) 2011-10-26
US20130197225A1 (en) 2013-08-01
DK2114405T3 (en) 2015-04-07
BRPI0720829B1 (pt) 2020-04-07
JP2010514725A (ja) 2010-05-06
ES2535040T3 (es) 2015-05-04
CY1116350T1 (el) 2017-03-15
CL2007003830A1 (es) 2008-07-11
HUE025032T2 (en) 2016-02-29
CO6190613A2 (es) 2010-08-19
TW200833677A (en) 2008-08-16
TWI388552B (zh) 2013-03-11
AU2007341356A1 (en) 2008-07-10
RU2463295C2 (ru) 2012-10-10
BRPI0720829A2 (pt) 2014-02-25
MY188367A (en) 2021-12-06
PT2114405E (pt) 2015-06-02
KR20090094166A (ko) 2009-09-03
AU2007341356B2 (en) 2013-08-29
US20120309969A1 (en) 2012-12-06
AR064545A1 (es) 2009-04-08
NO342150B1 (no) 2018-04-03

Similar Documents

Publication Publication Date Title
HRP20150573T1 (xx) KO-KRISTALNI OBLIK „A“ METILPARABENA OD [4-(3-FLUORO-5-TRIFLUOROMETIL-PIRIDIN-2-IL)-PIPERAZIN-1-IL]-[5-METANSULFONIL-2-((S)-2,2,2-TRIFLUORO-1-METIL-ETOKSI)-FENIL]-METANONA
CY2017038I2 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν 4-(4-(3-(4-χλωρο-3-τριφθορομεθυλ-φαινυλ)-ουρειδο)-3-φθορο-φαινοξυ)-πυριδιν-2-καρβοξυλικο οξυ για thν θεραπευτικη αγωγη υπερπολλαπλασιαστικων διαταραχων
BRPI0716880A2 (pt) Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
EP1885414A4 (en) DEVICE FOR MEDICAMENT ADMINISTRATION
ATE479673T1 (de) Hemmer der neubildung menschlicher immundefekt- viren
BRPI0821039A2 (pt) Formas sólidas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropa nocarboxamido)-3-meltipiridin-2-il)benzoico
EP2147437A4 (en) SEEDING REPLICATION
DK2094676T3 (da) Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
DK1981859T3 (da) Fremstilling af delmopinol
SMAP201000115A (it) Nuovi composti eterociclici e loro usi.
EP2244700A4 (en) KNOCKOUT MOUSE FOR STROMAL INTERACTION MOLECULE AND USES THEREOF
FI20050853A0 (fi) Käyttäjädatan hallinta
BRPI0817101A2 (pt) 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
NO345064B1 (no) Anvendelse av kombinasjonslegemidler, omfattende antimykotika
NO20076030L (no) Fremgangsmåte for fremstilling av hydroklorsilaner
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
BRPI0715342A2 (pt) Derivados de 6-carboxi-normorfinano, síntese e usos dos mesmos
DK1890684T3 (da) Behandling af søvn/vågenhedsforstyrrelser
DK2074123T3 (da) Nye anxiolytiske forbindelser
ATE499367T1 (de) 1,3-dihydroimidazol-2-thionderivate als inhibitoren von dopamin-beta-hydroxylase
FR2904315B1 (fr) Composes pyridaziniques et pyrroliques, procedes d'obtention et applications
DK1943242T3 (da) Piperidin-4-yl-pyridazin-3-ylamin-derivater som hurtigt opløsende antagonister af dopamin-2-receptorer
FI20065757A0 (fi) Beta-laktamaasin käyttö
BRPI0811527A2 (pt) Derivados de arilamida pirimidona
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater